News Mixed phase 3 results from J&J's esketamine depression drug Drug missed efficacy endpoint in older population
News Janssen's depression drug shows promise in phase 2 Ketamine may be best known as an anaesthetic illegally used as a party drug, but Janssen has shown that it could also be reformulated and used as a treatment for depression.
News Allergan and Gedeon Richter set to expand use of bipolar dru... Companies want Vraylar as option bipolar depression
News Takeda depression app impresses in pilot study App corresponds with standard cognitive and patient-reported assessment measures.
News Lundbeck trial investigates genetic causes of depression New study with 23andMe and Milken Institute looks to determine causes of depression.
News US researchers create AI capable of diagnosing depression Algorithm accurately detects depression from brain scans in 75% of cases.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.